Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 62,291 Shares of Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 62,291 shares of Immunome stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $26.23, for a total transaction of $1,633,892.93. Following the sale, the director owned 92,211 shares in the company, valued at approximately $2,418,694.53. This represents a 40.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Wednesday, August 12th, Isaac Barchas sold 11,048 shares of Immunome stock. The shares were sold at an average price of $27.25, for a total transaction of $301,058.00.
• On Monday, August 10th, Isaac Barchas sold 10,125 shares of Immunome stock. The stock was sold at an average price of $26.07, for a total transaction of $263,958.75.
• On Friday, August 7th, Isaac Barchas sold 15,248 shares of Immunome stock. The shares were sold at an average price of $26.06, for a total value of $397,362.88.
• On Thursday, August 6th, Isaac Barchas sold 20,840 shares of Immunome stock. The stock was sold at an average price of $26.06, for a total value of $543,090.40.
• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The shares were sold at an average price of $24.20, for a total value of $409,125.20.
• On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The shares were sold at an average price of $24.11, for a total value of $2,003,396.34.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The stock was sold at an average price of $22.59, for a total transaction of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The stock was sold at an average price of $21.12, for a total transaction of $2,134,176.00.

Immunome Trading Up 6.6%

Shares of IMNM opened at $27.99 on Thursday. The firm’s fifty day simple moving average is $21.89 and its two-hundred day simple moving average is $22.20. Immunome, Inc. has a 12 month low of $8.66 and a 12 month high of $28.04. The stock has a market capitalization of $3.17 billion, a P/E ratio of -11.06 and a beta of 2.08.

Immunome (NASDAQ:IMNM) last announced its earnings results on Tuesday, August 11th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.14). As a group, research analysts predict that Immunome, Inc. will post -2.06 EPS for the current fiscal year.

Institutional Trading of Immunome

A number of hedge funds and other institutional investors have recently made changes to their positions in IMNM. T. Rowe Price Investment Management Inc. boosted its position in shares of Immunome by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after acquiring an additional 5,003,824 shares during the period. BlackRock Inc. purchased a new stake in shares of Immunome in the second quarter worth $186,588,000. Vanguard Group Inc. grew its position in Immunome by 23.4% during the fourth quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after buying an additional 1,144,788 shares in the last quarter. Primecap Management Co. CA increased its stake in Immunome by 55.2% in the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after acquiring an additional 1,667,432 shares during the last quarter. Finally, State Street Corp boosted its position in shares of Immunome by 37.9% during the 4th quarter. State Street Corp now owns 3,868,000 shares of the company’s stock valued at $83,085,000 after acquiring an additional 1,064,027 shares during the last quarter. 44.58% of the stock is currently owned by institutional investors.

Immunome News Summary

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Truist raised its price target to $38 from $37 and maintained a “Buy” rating, implying substantial additional upside from recent levels. The upgraded outlook likely provided the strongest near-term support for Immunome (IMNM). Benzinga analyst price target update
• Positive Sentiment: Immunome reported its second-quarter 2026 results and provided a business update. Investors are likely focused on progress in the company’s clinical-stage antibody programs and its development pipeline, which remain key drivers of the stock’s valuation. Immunome second-quarter 2026 results and business update
• Neutral Sentiment: Director Isaac Barchas sold a combined 98,712 shares from August 10 through August 12 for approximately $2.6 million. The sales reduced his direct ownership to 92,211 shares, but each transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which may make the activity less indicative of a change in his outlook. The transactions were disclosed in SEC filings. Immunome director insider sales SEC filing
• Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, missing the consensus estimate of a $0.51 loss. The larger-than-expected loss underscores the company’s ongoing cash-burn and execution risks typical of a clinical-stage biotechnology company. Immunome quarterly earnings release

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Barclays began coverage on shares of Immunome in a research report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price target for the company. Citigroup restated a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a report on Friday, July 17th. Leerink Partners reduced their target price on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a report on Friday, May 15th. Finally, Truist Financial lifted their target price on Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a research note on Wednesday. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Immunome has a consensus rating of “Moderate Buy” and an average target price of $34.64.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.